SCHEMBL19956965

SCHEMBL19956965

Cc1cc2occ(C)c2cc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.57
ALDH1A1 P00352 6/20 0.47
KDM4E B2RXH2 4/20 0.47
KCNA3 P22001 4/20 0.44
HSD17B10 Q99714 3/20 0.40
HPGD P15428 2/20 0.40
TSHR P16473 2/20 0.40
POLB P06746 1/20 0.38
CD44 P16070 1/20 0.38
KCNA2 P16389 1/20 0.37
KCNA1 Q09470 1/20 0.37
ALDH1A2 O94788 1/20 0.37
ALDH2 P05091 1/20 0.37
ALDH1B1 P30837 1/20 0.37
ALDH1A3 P47895 1/20 0.37
MCL1 Q07820 1/20 0.37
ALOX15 P16050 1/20 0.37
SIRT1 Q96EB6 1/20 0.36
TOP2A P11388 2/20 0.35
AHR P35869 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17321069 0.89 ALDH1A1 (0.48) PTPN1ALDH1A1KDM4EKCNA3HSD17B10
SCHEMBL10981868 0.82 ALDH1A1 (0.43) PTPN1ALDH1A1KDM4EKCNA3HSD17B10
SCHEMBL17321061 0.82 ALDH1A1 (0.43) PTPN1ALDH1A1KDM4EKCNA3HSD17B10
SCHEMBL8404362 0.81 ALDH1A1 (0.53) PTPN1ALDH1A1KDM4EKCNA3HSD17B10
SCHEMBL19248240 0.81 ALDH1A1 (0.57) PTPN1ALDH1A1KDM4EKCNA3HSD17B10
SCHEMBL19248241 0.79 ALDH1A1 (0.67) ALDH1A1KDM4EKCNA3HSD17B10HPGD
SCHEMBL28946833 0.78 ALDH1A1 (0.43) PTPN1ALDH1A1KDM4EKCNA3HSD17B10
SCHEMBL23218192 0.77 PTPN1 (0.49) PTPN1ALDH1A1HPGDTSHRALOX15
SCHEMBL29853102 0.77 PTPN1 (0.49) PTPN1ALDH1A1HPGDTSHRALOX15
SCHEMBL28914825 0.76 PTPN1 (0.63) PTPN1ALDH1A1KDM4EKCNA3HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same Guangdong Raynovent Biotech Co., Ltd. (CN) 2020-05-19 US disclosed
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-04-25 US disclosed
EP-3293177-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME ABL1, LCK, ERBB2 PTPN1 29/4885ALDH1A1 2300/4885KDM4E 843/4885
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same ABL1, LCK, ERBB2 PTPN1 29/4885ALDH1A1 2300/4885KDM4E 843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.